RESEARCH & DEVELOPMENT:
Join Us On A Journey Of Innovation And Discovery.
Welcome to the dawn of innovation at Prakruti Life Science! With the establishment of our new Research and Development (R&D) department, we embark on a journey of discovery, exploration, and breakthroughs in pharmaceutical science.
Our plan of action for the R&D department is as follows:
Identifying Key Areas of Focus:
Our first step is to identify key areas of focus for our research initiatives. Through market analysis, competitor benchmarking, and consultation with industry experts, we will pinpoint areas of unmet medical need, emerging therapeutic trends, and opportunities for innovation within the pharmaceutical landscape.
Building a World-Class Team:
We are assembling a team of highly skilled scientists, researchers, and subject matter experts who will drive our R&D efforts forward. Drawing upon diverse backgrounds and expertise, our team will collaborate synergistically to generate novel ideas, conduct cutting-edge research, and translate discoveries into tangible solutions that benefit patients and healthcare providers.
Investing in Cutting-Edge Technology:
We are committed to equipping our R&D department with state-of-the-art technology, instrumentation, and infrastructure. From advanced laboratory equipment to computational tools and software platforms, we will provide our researchers with the resources they need to pursue innovative research projects and accelerate the pace of discovery.
Formulating Research Strategies:
Our R&D department will develop comprehensive research strategies and roadmaps to guide our efforts systematically. By aligning our research objectives with business goals, regulatory requirements, and patient needs, we will prioritize projects with the greatest potential for impact and success.
Collaborating with External Partners:
We recognize the value of collaboration and partnership in driving innovation. We will actively seek opportunities to collaborate with academic institutions, research organizations, biotechnology companies, and other stakeholders to leverage complementary expertise, share resources, and accelerate the development and commercialization of novel therapies and technologies.
At Prakruti Life Science, our R&D department is poised to be a catalyst for transformational change in the pharmaceutical industry. With a clear plan of action, a talented team, and a steadfast commitment to innovation, we are excited to embark on this journey of discovery and to unlock new possibilities that will shape the future of healthcare.
Long-term Objectives :
- Conduct market research to identify areas of high demand and growth in the life sciences industry.
- Develop a pipeline of new products and technologies that are ready for commercialization.
- Build a global network of partnerships and collaborations with leading research institutions and industry partners.
- Establish Prakruti Life Science as a leading player in the Pharmaceutical industry through innovative research and development.
Cutting-Edge Research Methodologies
Modern Science Contributing to Economic Growth
Focus on Health Market Demand Analysis
Dedicated Team Of Scientists And Researchers
MACHINERY & TECHNOLOGY
Explore The Future Of Natural Health With Our Advanced Technology.
Our R&D facilities are equipped with state-of-the-art machinery and technology, enabling us to conduct advanced research and development activities. Our commitment to technological excellence ensures that we stay at the forefront of the industry.
Contact Us For Excellent Service
Pioneering The Next Generation Of Wellness
Our R&D facilities are equipped with state-of-the-art machinery and technology, enabling us to conduct advanced research and development activities. Our commitment to technological excellence ensures that we stay at the forefront of the industry.
| SR. NO. | NAME OF PROJECTS | STRENGTH | THERAPEUTIC CATEGORY |
|---|---|---|---|
| 1 | Linagliptin Tablets | 2.5mg | Anti-Diabetic (Type 2) |
| 2 | Linagliptin Tablets | 5.0mg | |
| 3 | Linagliptin + Metformin HCL tablets | 2.5/500mg | Anti-Diabetic (Type 2) |
| 4 | Linagliptin + Metformin HCL tablets | 2.5/850mg | Anti-Diabetic (Type 2) |
| 5 | Linagliptin + Metformin HCL tablets | 2.5/1000mg | Anti-Diabetic (Type 2) |
| 6 | Linagliptin + Metformin HCL tablets | 5/500mg | Anti-Diabetic (Type 2) |
| 7 | Linagliptin + Metformin HCL tablets | 5/850mg | Anti-Diabetic (Type 2) |
| 8 | Linagliptin + Metformin HCL tablets | 5/1000mg | Anti-Diabetic (Type 2) |
| 9 | Apixaban Tablets | 2.5mg | Treat and prevent deep venous thrombosis |
| 10 | Apixaban Tablets | 5.0mg | Treat and prevent deep venous thrombosis |
| SR. NO. | NAME OF PROJECTS | STRENGTH | THERAPEUTIC CATEGORY |
|---|---|---|---|
| 1 | Loperamide + simethicone tablets | 2/125mg | Anti-diarrheal |
| 2 | Telmisartan Tablets IP | 20.0mg | Anti-hypertension |
| 3 | Telmisartan Tablets IP | 40.0mg | Anti-hypertension |
| 4 | Telmisartan Tablets IP | 80.0mg | Anti-hypertension |
| 5 | Sitagliptin Tablets | 25.0mg | Anti-Diabetic (Type 2) |
| 6 | Sitagliptin Tablets | 50.0mg | Anti-Diabetic (Type 2) |
| 7 | Sitagliptin Tablets | 100.0mg | Anti-Diabetic (Type 2) |
| 8 | Telmisartan + Hydrochlorothiazide Tablets | 40/12.5mg | Anti-hypertension |
| 9 | Telmisartan + Hydrochlorothiazide Tablets | 80/12.5mfg | Anti-hypertension |
| 10 | Rifaximin Tablets | 200mg | Anti-Bacterial (To treat travelers’ diarrhea) |
| 11 | Rifaximin Tablets | 400mg | Anti-Bacterial (To treat travelers’ diarrhea) |
| 12 | Rifaximin Tablets | 550mg | Anti-Bacterial (To treat travelers’ diarrhea) |
| 13 | Ticagrelor Tablets | 60.0mg | Antiplatelet (prevent Blood clot) |
| 14 | Ticagrelor Tablets | 90.0mg | Antiplatelet (prevent Blood clot) |
| 15 | Dapagliflozin tablets | 5.0mg | Anti-Diabetic (Type 2) |
| 16 | Dapagliflozin tablets | 10.0mg | Anti-Diabetic (Type 2) |
| 17 | Rivaroxaban Tablets | 2.5mg | Treat and prevent deep venous thrombosis |
| 18 | Rivaroxaban Tablets | 5.0mg | Treat and prevent deep venous thrombosis |
| 19 | Rivaroxaban Tablets | 10.0mg | Treat and prevent deep venous thrombosis |
| 20 | Rivaroxaban Tablets | 15.0mg | Treat and prevent deep venous thrombosis |
| 21 | Rivaroxaban Tablets | 20.0mg | Treat and prevent deep venous thrombosis |
| SR. NO. | NAME OF PROJECTS | STRENGTH | THERAPEUTIC CATEGORY |
|---|---|---|---|
| 1 | Sumatriptan + Naproxen Tablets | 85/500mg | To treat acute migraine |
| 2 | Colchicine tablets | 0.5mg | Gout |
| 3 | Colchicine tablets | 0.6mg | Gout |
| 4 | Ursodeoxycholic acid tablet | 600 mg | treatment of cholestatic liver disease, bile acid |
| 5 | Ursodeoxycholic acid tablet | 300 mg | treatment of cholestatic liver disease, bile acid |
| 6 | Ursodeoxycholic acid tablet | 150 mg | treatment of cholestatic liver disease, bile acid |
DEPTH INSIGHT
Download The Prakruti Life Science Brochure
Dive into the world of innovative health solutions with Prakruti Life Science. Our brochure provides an in-depth look at our groundbreaking research, high-quality products, and tailored services designed to enhance health and well-being.
